Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NamePegbio Co-B
Stock Code02565
Company Full NamePegBio Co., Ltd.
Industry醫療保健
Principal Activities公司成立于2008年,是一家專注于自主研究及開發慢性病創新療法的生物技術公司,重點關注內分泌代謝領域。
Listing Date2025-05-27
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國浙江省杭州市拱墅區皓章大廈1幢606室
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.pegbio.com/
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism 18A生物科技
Offer PriceHK$ 15.60 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 7,800
Par ValueTo be extracted
Offer Period2025-05-19 to 2025-05-22
Global Offering Shares19,283,500 shares
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone Share49.7%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 300,822,600

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 7,800
2 lots 1,000 HK$ 15,600
3 lots 1,500 HK$ 23,400
4 lots 2,000 HK$ 31,200
5 lots 2,500 HK$ 39,000
6 lots 3,000 HK$ 46,800
7 lots 3,500 HK$ 54,600
8 lots 4,000 HK$ 62,400
9 lots 4,500 HK$ 70,200
10 lots 5,000 HK$ 78,000
12 lots 6,000 HK$ 93,600
14 lots 7,000 HK$ 109,200
16 lots 8,000 HK$ 124,800
18 lots 9,000 HK$ 140,400
20 lots 10,000 HK$ 156,000
30 lots 15,000 HK$ 234,000
40 lots 20,000 HK$ 312,000
50 lots 25,000 HK$ 390,000
60 lots 30,000 HK$ 468,000
70 lots 35,000 HK$ 546,000
80 lots 40,000 HK$ 624,000
90 lots 45,000 HK$ 702,000
100 lots 50,000 HK$ 780,000
120 lots 60,000 HK$ 936,000
140 lots 70,000 HK$ 1,092,000
160 lots 80,000 HK$ 1,248,000
180 lots 90,000 HK$ 1,404,000
200 lots 100,000 HK$ 1,560,000
300 lots 150,000 HK$ 2,340,000
400 lots 200,000 HK$ 3,120,000
500 lots 250,000 HK$ 3,900,000
600 lots 300,000 HK$ 4,680,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
700 lots 350,000 HK$ 5,460,000
800 lots 400,000 HK$ 6,240,000
900 lots 450,000 HK$ 7,020,000
1,000 lots 500,000 HK$ 7,800,000
1,100 lots 550,000 HK$ 8,580,000
1,200 lots 600,000 HK$ 9,360,000
1,300 lots 650,000 HK$ 10,140,000
1,400 lots 700,000 HK$ 10,920,000
1,500 lots 750,000 HK$ 11,700,000
1,600 lots 800,000 HK$ 12,480,000
1,700 lots 850,000 HK$ 13,260,000
1,928 lots 964,000 HK$ 15,038,400

Stock Connect Inclusion Analysis

HK Market Cap HK$ 9.35B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceRMB 28.39 million
Listing Expenses~HK$ 69,100,000
Listing Expenses / Funds Raised~23.0%
Total Pre-IPO Investmentapproximately USD 50.3 million
First Day CloseHK$ 11.56
First Day OpenHK$ 13.0
First Day Change-25.90%
First Day Volume11264800.0
First Day Turnover150891000.0
Use of Proceeds
1、約116.5百萬港元(或約50.2%)用于撥付核心產品PB-119的商業化及適應癥擴展; 2、約79.9百萬港元(或約34.5%)用于撥付主要產品PB-718的進一步開發; 3、約12.2百萬港元(或約5.3%)用于撥付其他管線候選產品正在進行及計劃進行的研發; 4、約2.3百萬港元(或約1.0%)將用于業務開發活動及加強海外業務; 5、約20.9百萬港元(或約9.0%)將用作營運資金及其他一般公司用途。

Underwriting Syndicate

Sole Sponsor (1)
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (5)
中国国际金融香港证券有限公司 CE AEN894 民银证券有限公司 CE APU820 农银国际证券有限公司 CE ACX411 中银国际亚洲有限公司 CE AET863 建银国际金融有限公司 CE AJO225
Joint Bookrunners (14)
中国国际金融香港证券有限公司 CE AEN894 民银证券有限公司 CE APU820 农银国际证券有限公司 CE ACX411 中银国际亚洲有限公司 CE AET863 建银国际金融有限公司 CE AJO225 Livermore Holdings Limited CE BJN764 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 SPDB International Capital Limited CE BFZ375 Eddid Securities and Futures Limited CE BHT550 SINOLINK SECURITIES (HONG KONG) COMPANY LIMITED CE AAI195 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536 广发证券(香港)经纪有限公司 CE AOB364 中国银河国际证券(香港)有限公司 CE AXM459 CEB International Capital Corporation Limited CE BGH296
Joint Lead Managers (14)
中国国际金融香港证券有限公司 CE AEN894 民银证券有限公司 CE APU820 农银国际证券有限公司 CE ACX411 中银国际亚洲有限公司 CE AET863 建银国际金融有限公司 CE AJO225 Livermore Holdings Limited CE BJN764 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 SPDB International Capital Limited CE BFZ375 Eddid Securities and Futures Limited CE BHT550 SINOLINK SECURITIES (HONG KONG) COMPANY LIMITED CE AAI195 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536 广发证券(香港)经纪有限公司 CE AOB364 中国银河国际证券(香港)有限公司 CE AXM459 CEB International Capital Corporation Limited CE BGH296

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 益泽康瑞医药(香港)有限公司 149,518,200 HKD — 49.70% — 6 months 2025-11-27

Directors & Management

PositionChinese nameEnglish Name
ChairmanMichael Min XU—
Company Secretary黃一峰,郭恩廷—
No director data available.

Major Shareholders

Major Shareholders & HoldingsMichael Min XU(15.05%),Mingly China Growth Fund, L.P.(9.03%),上海蘇頡企業管理咨詢合伙企業(有限合伙)(7.56%),元生創投(5.26%)
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
Underlying data failed quality checks; AI interpretation downgraded and shown for reference only.

Market Sentiment

The IPO was met with overwhelming demand, achieving an oversubscription ratio of 743.78x. The hit rate of just 20.95% underscores intense competition for allocations. Clawback C triggered significant reallocation to the public tranche, reflecting strong retail interest. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

Tier distribution data is not provided, precluding analysis of allocation anomalies or broker fee efficiency. Without detailed subscription figures by tier, no pattern can be observed. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Demographic breakdowns are entirely missing from the dataset, with holder counts and regional percentages set to zero. It is unclear whether mainland or local participation drove the demand. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Pegbio Co-B (02565) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect